Karl Utermohlen

Karl Utermohlen

Recent Articles

#METOO Trending: The Sad Reason ‘Me Too’ Is Filling Social Media Feeds

The hashtag #METOO has been trending on Facebook, Twitter and other social media avenues in support for women who've been sexually harassed.

Krack Hack: What Every Wi-Fi User Must Do ASAP

The Krack Hack is an attack that occurs in Wi-Fi networks that are not properly secured. Here's how you can avoid falling victim to it.

The Most Popular Halloween Candy by State for 2017

What is the most popular Halloween candy for each state? We have the full list for you here, according to a poll that surveyed 40,000 people.

3 Stocks to Watch on Monday: Bombardier Inc (BDRBF), Microsoft Corporation (MSFT) and Viacom, Inc. (VIAB)

Bombardier (BDRBF) may sell part of its aerospace business, Microsoft (MSFT) builds treehouses and Viacom's (VIAB) Spectrum decision looms.

7 Happy Halloween Images to Post on Facebook, Twitter, Instagram

Happy Halloween! We have compiled seven of the best Halloween images in honor of the popular holiday; you can share these on social media.

Seasonal Jobs 2017: Amazon Hiring 120,000 for the Holidays

More and more companies are adding seasonal jobs to ramp up the holiday shopping season, and Amazon (AMZN) is no exception, adding 120,000.

New FB Feature: How to ‘Order Food’ on Facebook

You can now order food on Facebook (FB) through an app that is partners with Delivery.com and various other online food delivery services.

Social Security Increase for 2018: 9 Things to Know

The Social Security increase for 2018 will be the highest bump since 2012. Here are nine things to know about the changes for retirees.

Friday the 13th, 2017: Flight 666 Safely Arrives in HEL for the Last Time

Flight 666 on Friday the 13th arrived safely in HEL, which is the Helsinki airport, for the last time as the airline will retire the number.

3 Stocks to Watch on Friday: Baxter International Inc (BAX), Exfo Inc (EXFO) and Spark Therapeutics Inc (ONCE)

Baxter International (BAX) outlook down, Exfo (EXFO) earnings impress and Spark Therapeutics' (ONCE) blindness drug may be approved.